The Association of Lipoprotein(a) and Neutrophil-to-Lymphocyte Ratio Combination with Atherosclerotic Cardiovascular Disease in Chinese Patients

被引:3
|
作者
Wang, Xiaoyu [1 ]
Chen, Xiaoli [1 ]
Wang, Yanfang [1 ]
Peng, Sheng [2 ]
Pi, Jingjiang [3 ]
Yue, Jinnan [1 ]
Meng, Qingshu [1 ]
Liu, Jie [1 ]
Zheng, Liang [1 ,4 ]
Chan, Paul [5 ]
Tomlinson, Brian [6 ]
Liu, Zhongmin [1 ,7 ]
Zhang, Yuzhen [1 ,7 ]
机构
[1] Tongji Univ, Shanghai East Hosp, Shanghai Heart Failure Res Ctr, Res Ctr Translat Med,Key Lab Arrhythmias,Minist Ed, Shanghai 200092, Peoples R China
[2] Tongji Univ, Shanghai East Hosp, Sch Med, Dept Trauma, Shanghai 200120, Peoples R China
[3] Tongji Univ, Shanghai East Hosp, Sch Med, Dept Cardiol, Shanghai, Peoples R China
[4] Tongji Univ, Jian Hosp, Shanghai East Hosp, Sch Med, Jian 343006, Peoples R China
[5] Taipei Med Univ, Wan Fang Hosp, Dept Internal Med, Div Cardiol, Taipei, Taiwan
[6] Macau Univ Sci & Technol, Fac Med, Macau, Peoples R China
[7] Tongji Univ, Shanghai East Hosp, Shanghai Heart Failure Res Ctr, Res Ctr Translat Med,Key Lab Arrhythmias,Minist Ed, 150 Jimo Rd,Pudong 15New Dist, Shanghai 200092, Peoples R China
基金
中国国家自然科学基金;
关键词
lipoprotein(a); neutrophil to lymphocyte ratio; ASCVD and coronary artery plaque; CORONARY-ARTERY-DISEASE; C-REACTIVE PROTEIN; PLASMINOGEN ACTIVATION; HEART-DISEASE; RISK; MORTALITY; INHIBITION; AMERICAN; DOMAINS; EVENTS;
D O I
10.2147/IJGM.S410840
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: The association of lipoprotein(a) [Lp(a)] with atherosclerotic cardiovascular disease (ASCVD) risk can be modified by chronic systemic inflammation. The neutrophil-to-lymphocyte ratio (NLR) is a reliable and easily available marker of immune response to various infectious and non-infectious stimuli. The purpose of this study was to assess the combined effects of Lp(a) and NLR in predicting the ASCVD risk and coronary artery plaque traits.Methods: This study included 1618 patients who had coronary computed tomography angiography (CTA) with risk assessment of ASCVD. CTA was used to evaluate the traits of coronary atherosclerotic plaques, and the association of ASCVD with Lp(a) and NLR was assessed by multivariate logistic regression models.Results: Plasma Lp(a) and NLR were significantly increased in patients having plaques. High Lp(a) was defined as the plasma Lp(a) level > 75 nmol/L and high NLR as NLR > 1.686. The patients were grouped into four categories according to normal or high NLR and plasma Lp(a) as nLp(a)/NLR-, hLp(a)/NLR-, nLp(a)/NLR+ and hLp(a)/NLR+. The patients in the latter three groups had higher risk of ASCVD compared to the reference group nLp(a)/NLR-, with the highest ASCVD risk in the hLp(a)/NLR+ group (OR = 2.39, 95% CI = 1.49-3.83, P = 0.000). The occurrence of unstable plaques was 29.94% in the hLp(a)/NLR+ group, which was significantly higher than groups nLp(a)/NLR+, hLp(a)/NLR-and nLp(a)/NLR-with 20.83%, 26.54% and 22.58%, respectively, and there was a significantly increased risk of unstable plaque in the hLp(a)/NLR+ group compared to the nLp(a)/NLR-group (OR = 1.67, 95% CI = 1.04-2.68, P = 0.035). The risk of stable plaque was not significantly increased in the hLp(a)/NLR+ group compared to the nLp(a)/NLR-group (OR = 1.73, 95% CI = 0.96-3.10, P = 0.066).Conclusion: The concomitant presence of elevated Lp(a) and higher NLR is associated with increased unstable coronary artery plaques in patients with ASCVD.
引用
收藏
页码:2805 / 2817
页数:13
相关论文
共 50 条
  • [1] Association of Neutrophil-to-Lymphocyte Ratio with Atherosclerotic Cardiovascular Disease and Kidney Outcomes in CKD
    Mahalwar, Gauranga
    Chen Zhengyi
    Horwitz, Edward J.
    Taliercio, Jonathan J.
    Rahman, Mahboob
    Dobre, Mirela A.
    Brateanu, Andrei
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2024, 35 (10):
  • [2] THE INTERPLAY BETWEEN LIPOPROTEIN(A) AND INFLAMMATORY MARKERS IN ATHEROSCLEROTIC CARDIOVASCULAR DISEASE (ASCVD): A FOCUS ON NEUTROPHIL-TO-LYMPHOCYTE RATIO (NLR)
    Basaran, Ozcan
    Karaaslan, Umutcan
    Gungor, Baris
    ATHEROSCLEROSIS, 2024, 395
  • [3] The associations between neutrophil-to-lymphocyte ratio and the Chinese Visceral Adiposity Index, and carotid atherosclerosis and atherosclerotic cardiovascular disease risk
    Li, Baoli
    Lai, Xiaoying
    Yan, Chuanjie
    Jia, Xiaoping
    Li, Yingjia
    EXPERIMENTAL GERONTOLOGY, 2020, 139
  • [4] Association between platelet-to-lymphocyte ratio and neutrophil-to-lymphocyte ratio with disease activity in Takayasu arteritis patients
    李治琴
    ChinaMedicalAbstracts(InternalMedicine), 2018, 35 (04) : 214 - 215
  • [5] Association of neutrophil-to-lymphocyte ratio and microalbuminuria in patients with normal eGFR
    Kutlugun, Aysun Aybal
    Ebinc, Fatma Ayerden
    Ozturk, Mujgan Tek
    Efe, Fatma Kaplan
    Karadag, Ibrahim
    Eser, Murat
    Unsal, Oktay
    Karakaya, Serdar
    ROMANIAN JOURNAL OF INTERNAL MEDICINE, 2018, 56 (01) : 21 - 26
  • [6] Association of neutrophil-to-lymphocyte ratio and risk of cardiovascular and all-cause mortality in hypertension patients
    Hong, Shaoqing
    He, Hongxia
    Fang, Peng
    Liu, Shuai
    Chen, Changyi
    HELIYON, 2024, 10 (06)
  • [7] Association of glucose to lymphocyte ratio with the risk of death in patients with atherosclerotic cardiovascular disease
    Lei, Jinglin
    Duan, Wentao
    Yao, Xiaoxi
    Hu, Zheng
    Fan, Huihui
    Liu, Yifan
    Zhong, Wenjian
    Li, Haipeng
    SCIENTIFIC REPORTS, 2025, 15 (01):
  • [8] Neutrophil-to-Lymphocyte Ratio in Patients With Cirrhosis
    Bakshi, Satvinder Singh
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2019, 17 (04) : 799 - 799
  • [9] Neutrophil-to-lymphocyte ratio in trauma patients
    Park, Joon Min
    JOURNAL OF TRAUMA AND ACUTE CARE SURGERY, 2017, 82 (01): : 225 - 226
  • [10] Association between the variability of non-high-density lipoprotein cholesterol and the neutrophil-to-lymphocyte ratio in patients with coronary heart disease
    Chen, Yifan
    Zhang, Sisi
    Tao, Yecheng
    Hu, Wenyi
    Li, Duanbin
    Shen, Xiaohua
    Li, Ya
    Lin, Maoning
    Zhang, Wenbin
    Liu, Xianglan
    Xie, Daqi
    FRONTIERS IN CARDIOVASCULAR MEDICINE, 2023, 10